Two members of the UCLA Broad Stem Cell Research Center have received a grant for work that could be helpful in developing a vaccine.
Researchers will focus on an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy the virus.
The findings are critical for researchers aiming to develop muscle stem cells in the lab that can be used to combat disease.
The findings could eventually lead to new drugs to treat or prevent lung cancer.
UCLA-led research uncovers new details about the Foxp1 gene, which also is involved in timing of neuron production.
UCLA researchers were part of an international team to test gene therapy in people with X-linked chronic granulomatous disease.
The advance could help scientists identify drugs to treat fibrosis, which plays a role in chronic kidney disease, liver cirrhosis and many other conditions.
Research brief: The new method, using robotics, will speed up how researchers test for therapies that block the metabolism of non-small-cell lung cancer tumors.
The finding could lead to better treatments for leukemia and other blood diseases.
Funds from California’s stem cell agency will support research on a blinding eye disease, cancer and an immune disorder.
The study, conducted in mice, is the first to show that creatine uptake is critical to the anti-tumor activities of what is known as killer T cells, the foot soldiers of the immune system.
Findings of the research conducted in mice could inform the development of therapies that reduce the time it takes for people to recover from nerve injuries.
The researchers’ goal was to create a therapy that would permanently boost the body’s ability to naturally produce more iNKT cells.
The new hydrogel is more porous and effective in promoting tissue repair and regeneration compared to hydrogels that are currently available.
Of mice that received high doses of radiation, nearly all that received a compound developed by UCLA scientists survived.
The observation helps explain why, as people age, the prostate tends to grow, leading to an increased risk for cancer and other conditions.
The discoveries by an interdisciplinary team of UCLA scientists could improve the diagnoses of these aggressive cancers.
50% of treatments could have been avoided using the new tool, a UCLA-led study finds.
A drug that suppresses the gene could lead to the first pill to treat stroke’s aftermath.
The findings could pave the way for new treatments for heart valve disorders, which can be caused by congenital defects, aging or disease.
A technique they developed coaxes pluripotent stem cells — which can can be grown indefinitely in the lab — into becoming mature T cells capable of killing tumor cells.
The condition, which affects red blood cells’ ability to produce regulatory T cells, can affect the intestines, pancreas and thyroid, as well as other parts of the body.
The findings could lead to a better understanding of the metabolic needs of many different types of cancer.
Previous research hinted that small cell cancers from different organs may be driven by common mechanisms, but the new study is the first to so clearly describe the steps in their evolution.
The study could lead to new treatments for a range of advanced epithelial cancers such as lung, prostate and bladder cancers.